Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818762 | 0.83 | POLB (0.54) | L3MBTL1NPSR1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL14803776 | 0.83 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1NPSR1LMNA | |
| SCHEMBL29856438 | 0.76 | MDM4 (0.46) | LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL2033252 | 0.76 | KDM4C (0.50) | LMNAKMT2AKDM4E | |
| SCHEMBL30600744 | 0.76 | KDM4C (0.50) | LMNAKMT2AKDM4E | |
| SCHEMBL26229535 | 0.76 | TAAR1 (0.62) | LMNAKMT2ASMN1; SMN2PKMKDM4E | |
| SCHEMBL26623650 | 0.75 | MAPT (0.43) | LMNAKMT2A | |
| SCHEMBL692100 | 0.75 | HPGD (0.49) | ALDH1A1GAAKMT2APKMKDM4E | |
| SCHEMBL12320459 | 0.74 | KDM4D (0.68) | ALDH1A1L3MBTL1NPSR1LMNAKMT2A | |
| SCHEMBL38664985 | 0.74 | LMNA (0.48) | ALDH1A1GAAL3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169246-B2 | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-10-27 | — | — | US | disclosed |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-21 | — | — | US | disclosed |
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079337-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, COQ8A, CYP1A2 | ALDH1A1 88/4885GAA 1467/4885L3MBTL1 4514/4885 |
| US-20140235616-A1 | PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP1A2, COQ8A | ALDH1A1 97/4885GAA 1631/4885L3MBTL1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.